Zusammenfassung
Pflegende übernehmen vor, während und nach onkologischen Therapien eine wichtige Rolle bei der Prophylaxe und der Symptomkontrolle von Übelkeit und Erbrechen. Fundierte Kenntnisse zur Behandlung und Entstehung, sowie zu Auswirkungen von Übelkeit und Erbrechen sorgen für zielgerichtete pflegerische Interventionen und können an Patienten und Angehörige weitergegeben werden.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Aapro M et al. (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23: 1986–92
Basch E et al. (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29: 4189–98
Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0; Published: May 28, 2009 (v4.03: June 14, 2010); U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, National Cancer Institute
Einhorn LH et al. (2011) Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer 19 Suppl 1: S1–S4
Feyer PC, Maranzano E, Molassiotis A et al. (2011) Radiotherapy-induced nausea and vomiting (RINV): MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Support Care Cancer 19: Suppl 1:S5–14
Gralla RJ et al. (1999) Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines. J Clin Oncol 17: 2971–2994
Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329: 1790–6
Grunberg SM et al. (2004). Incidence of chemotherapy- induced nausea and emesis after modern antiemetics: Perception versus reality. Cancer, 100, 2261–2268
Grunberg S et al. (2011) Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE. J Clin Oncol 29: 1495–1501
Majem M et al. (2011). Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Supportive Care in Cancer, 19, 1983–1990
Marx WM et al. (2013) Ginger (Zingiber officinale) and chemotherapy-induced nausea and vomiting: a systematic literature review. Nutr Rev71:245-54
Navari RM (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9: 188–95
NCCN Clinical Practice Guidelines in Oncology, Antiemesis, Retrieved Version 2.2014
Roila F et al. (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherpay-an radiotherpy -induced nausea and vomiting and of nausea and vomiting tin advanced cancer patients. Ann Oncol 27: Supp 5 v119–v133
Ryan JL et al. (2012) Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer; 20:1479–89
Saito M, Aogi K, Sekine I et al. (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10: 115–24
Weiterführende Literatur
Grunberg SM et al. (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art. Support Care Cancer 19 Suppl 1: S43–7
Herrstedt J et al. (2011) Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer19: S15–S23
Kris MG et al. (2011) Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 19 Suppl 1: S25–S32
Molassiotis A, Aapro M et al. (2014) J Pain Symptom Manage, 47(5): 839–848
Oliver I et al. (2011) Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic Potenzial. Support Care Cancer 19 Suppl: S33–S36
Roila F et al. (2011) Delayed emesis: moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Support Care Cancer 19 Suppl 1: S57–S62
Internetadressen
European Medical Oncology Society: (www.esmo.org Antiemetic Guidelines)
Multinational Association for Supportive Care in Cancer: www.mascc.org (Antiemetic Guidelines 2013)
National Comprehensive Cancer Network (www.nccn.org Antiemesis Guidelines)
Oncology Nursing Society: www.ons.org (Evidence based practice-PEP (Putting Evidence into Practice) – nausea/vomiting)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer-Verlag GmbH Deutschland
About this chapter
Cite this chapter
Hlawatsch, C., Oechsle, K. (2017). Übelkeit und Erbrechen. In: Margulies, A., Kroner, T., Gaisser, A., Bachmann-Mettler, I. (eds) Onkologische Krankenpflege. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-53955-2_21
Download citation
DOI: https://doi.org/10.1007/978-3-662-53955-2_21
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-53954-5
Online ISBN: 978-3-662-53955-2
eBook Packages: Medicine (German Language)